AAPS eChalk Talk: Quantitation of a GLP-1 Agonist Panel to Support Microdosing Programs

Nearly 12% of adults in the United States have reported using a GLP-1 agonist. The benefits of weight loss, appetite control, reduced inflammation and improved metabolic health is often overshadowed by the severe side effects of nausea, vomiting, diarrhea, bloating, acid reflux, stomach aches, headache, fatigue, dizziness and reduced appetite. In order to minimize these side effects many companies are microdosing these compounds with the additional advantage of reducing the cost of the treatment. These microdoses can be up to 20-fold lower than the typical therapeutic range. This dose reduction will result in clinical studies that must be conducted in order to determine the PK and efficacy of these compounds.

The bioanalysis of these compounds can be challenging since the assay sensitivity must be up to 20-fold lower than the previous methods. The presentation will explain the practical aspects of sample preparation and LC-MS/MS analysis to simultaneously measure semaglutide, liraglutide, exenatide and taspoglutide to support GLP-1 agonist microdosing clinical studies.

This webinar provides an opportunity for laboratory personnel and development strategists to efficiently develop robust methods for the bioanalysis of GLP-1 agonists microdosed in clinical studies.

Presented by: Brenton Poirier, PhD, Senior Scientist
Moderated by: Chad Christianson, Analytical Development Manager

Register Here

Use the contact form below to meet with an Alturas representative during ASMS.

"*" indicates required fields

First Name*

Last Name*

Company*

Email*

Phone*

Interest*

Select Your InterestMethod Development/ValidationPre-clinical Sample AnalysisClinical Sample AnalysisPharmacokinetic/Toxicokinetic AnalysisSample StorageOther

Message

Consent*

I consent to receiving communications from Alturas Analytics. By clicking submit, I agree with the storage and handling of my data by Alturas Analytics.

Please review our Privacy Policy for more information. You can opt out at any time.

CAPTCHA